ArticleAnnals of surgical oncology2026
Minimally Invasive Gastrectomy for Borrmann Type IV Gastric Cancer: An Oncologically Sound Alternative to Open Surgery.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression.Journal of gastrointestinal oncology · 2026Article
- Redefining the Role of Splenectomy in Scirrhous Gastric Cancer: Toward a Selective Multimodal Strategy.Annals of gastroenterological surgery · 2026Review
- Borrmann type IV gastric cancer exhibits distinct clinicopathological features and extremely poor prognosis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPrevious studies have validated the oncologic safety of minimally invasive surgery (MIS) for advanced gastric cancer, but the feasibility of applying MIS to treat Borrmann type IV gastric cancer remains unclear. Given its distinct clinicopathological features, poor prognosis, and technical complexities in surgery, further investigation is needed. This study aimed to compare the surgical and oncological outcomes between open surgery and MIS in patients with Borrmann type IV gastric cancer.
methodsWe retrospectively analyzed data from 1025 patients who underwent open (n = 888) or minimally invasive (n = 137) gastrectomy for Borrmann type IV gastric cancer between 2003 and 2021. Propensity score matching was performed to balance baseline characteristics, and short- and long-term outcomes were compared between the matched groups.
resultsAfter propensity score matching, each group included 112 matched patients. The MIS group had longer operative times (p < 0.001) but shorter hospital stays (p < 0.001) than the open surgery group. Other perioperative outcomes showed no significant differences. Overall and recurrence-free survival were comparable between the two groups (p = 0.741 and p = 0.707, respectively). Adjusted hazard ratios for death and recurrence following MIS compared with open surgery were 1.20 (95% confidence interval 0.78-1.85, p = 0.396) and 1.22 (95% confidence interval 0.83-1.79, p = 0.308), respectively.
conclusionOur findings suggest that MIS for Borrmann type IV gastric cancer may offer long-term oncologic outcomes comparable to those with open surgery while preserving the inherent benefits of MIS.
Indexed as
Identifiers
41105369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.